Athira Pharma Logo RGB@1200px.jpg
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
March 08, 2024 07:00 ET | Athira Pharma, Inc.
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s & Parkinson’s Diseases at AD/PD™ 2024
tiziana-logo.png
Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease
March 05, 2024 07:00 ET | Tiziana Life Sciences Ltd.
Data shows reduction of microglia activation and improvement in behavior in rodent models of Alzheimer’s disease (AD) and Parkinson’s disease (PD)Nasal anti-CD3 reduced hemorrhage and edema that...
Nature Medicine Publ
Nature Medicine Publication Highlights Potential for ONWARD® ARC Therapy™ to Improve Mobility After Parkinson’s Disease
November 06, 2023 12:13 ET | ONWARD Medical NV
EINDHOVEN, the Netherlands, Nov. 06, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore...
ONWARD versterkt man
ONWARD versterkt management met kernfuncties in Klinische & Regelgevende en Marketingafdelingen
November 06, 2023 12:13 ET | ONWARD Medical NV
EINDHOVEN, Nederland, LAUSANNE, Zwitserland & BOSTON, MA, VS, Nov. 06, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), het medische technologiebedrijf dat innovatieve therapieën...
ONWARD renforce son
ONWARD renforce son management avec des nominations clés dans le domaine clinique et réglementaire et en marketing
November 06, 2023 12:13 ET | ONWARD Medical NV
EINDHOVEN, Pays-Bas, LAUSANNE, Suisse, et BOSTON, MA, Etats-Unis, 06 nov. 2023 (GLOBE NEWSWIRE) -- ONWARD Medical SA (Euronext: ONWD), société de technologie médicale créant des thérapies innovantes...
ONWARD verstärkt Füh
ONWARD verstärkt Führungsteam auf Schlüsselpositionen in den Bereichen Clinical & Regulatory sowie Marketing
November 06, 2023 12:13 ET | ONWARD Medical NV
EINDHOVEN, Niederlande, LAUSANNE, Schweiz und BOSTON, MA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Das Medizintechnikunternehmen ONWARD Medical N.V. (Euronext: ONWD), das innovative Therapien zur...
logo.jpg
AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
November 03, 2023 07:00 ET | AC Immune SA
AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update Results from amyloid plaque reduction analysis (Abeta-PET) after 6 months of treatment with ACI-24.060 in ABATE...
logo.jpg
AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic
October 27, 2023 07:00 ET | AC Immune SA
PRESS RELEASE AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic ACI-125891 delivers the...
logo.jpg
AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023
September 05, 2023 07:00 ET | AC Immune SA
AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023 Lausanne, Switzerland, September 05, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage...
logo.jpg
AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
August 04, 2023 07:00 ET | AC Immune SA
AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate UpdateReceived FDA Fast Track Designation for ACI-24.060 anti-amyloid-beta (Abeta) active immunotherapy to treat...